Evaluation of Adjunctive Azithromycin Prophylaxis in Women Undergoing Cesarean Delivery in a Setting With Low Baseline Incidence of Surgical Site Infection.


Journal

Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
ISSN: 1701-2163
Titre abrégé: J Obstet Gynaecol Can
Pays: Netherlands
ID NLM: 101126664

Informations de publication

Date de publication:
09 2021
Historique:
received: 16 08 2020
revised: 08 12 2020
accepted: 08 12 2020
pubmed: 8 1 2021
medline: 29 10 2021
entrez: 7 1 2021
Statut: ppublish

Résumé

The purpose of this quality improvement study was to determine the effect of adding azithromycin to standard antibiotic prophylaxis on the rates surgical site infection (SSI) in women undergoing both elective and non-elective cesarean deliveries at our centre. A before-and-after quality improvement study was conducted at the Regina General Hospital in Regina, Saskatchewan. Data collected from 989 women who had a caesarean delivery between June 1, 2016 and June 30, 2017 were compared with those from 1033 women who had a caesarean delivery between August 1, 2017 and July 31, 2018, after the introduction of adjunctive azithromycin prophylaxis. The primary outcome measure was the change in the incidence of SSI up to 30 days following surgery. Secondary outcome measures included timing of azithromycin prophylaxis and the number of women who did not receive azithromycin. Surgical site infection rates decreased from 3.5% to 2.9% after adjunctive azithromycin prophylaxis was introduced. The absolute reduction in SSIs of 0.6% was not statistically significant (P = 0.42). There were no differences in SSI rates between the elective and non-elective subgroups. Adding azithromycin to the standard antibiotic prophylaxis for cesarean delivery showed no statistically significant reduction in SSI rates in a population with low baseline rates of SSI.

Identifiants

pubmed: 33412302
pii: S1701-2163(20)31038-0
doi: 10.1016/j.jogc.2020.12.016
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Azithromycin 83905-01-5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1062-1068.e2

Informations de copyright

Copyright © 2021 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.

Auteurs

Corrine Jabs (C)

Department of Obstetrics and Gynecology, University of Saskatchewan, Regina, SK. Electronic address: corrinejabs@hotmail.com.

Maria Giroux (M)

Department of Obstetrics and Gynecology, University of Saskatchewan, Regina, SK.

Jessica Minion (J)

Department of Pathology and Laboratory Medicine, University of Saskatchewan, Regina, SK; Roy Romanow Provincial Laboratory, Saskatchewan Health Authority, Regina, SK.

Erwin Karreman (E)

Research and Performance Support, Saskatchewan Health Authority, Regina, SK.

Meredith Faires (M)

Roy Romanow Provincial Laboratory, Saskatchewan Health Authority, Regina, SK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH